Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714181 | 0.88 | TSHR (0.41) | TSHRACHENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL982199 | 0.87 | TRPA1 (0.37) | TSHRACHENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2761711 | 0.83 | MEN1 (0.32) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL322239 | 0.80 | MEN1 (0.35) | TSHRNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8855149 | 0.80 | MEN1 (0.35) | TSHRNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5325193 | 0.79 | ELANE (0.38) | SMN1; SMN2CYP3A4TDP1ALDH1A1GAA | |
| SCHEMBL2458589 | 0.79 | ELANE (0.38) | NPC1RAB9ASMN1; SMN2CYP3A4TDP1 | |
| SCHEMBL3223109 | 0.77 | CYP1A2 (0.40) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL12816261 | 0.77 | CYP1A2 (0.33) | TSHRCYP1A2 | |
| SCHEMBL3912578 | 0.77 | NPC1 (0.35) | TSHRACHENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240114784-A1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEM, LTD. (KR) | 2024-04-04 | — | — | US | claimed |
| EP-4270508-A1 | ORGANIC LIGHT EMITTING DEVICE | Lg Chem, Ltd. (KR) | 2023-11-01 | — | — | EP | claimed |
| US-20230232700-A1 | METHOD FOR PATTERNING A COATING ON A SURFACE AND DEVICE INCLUDING A PATTERNED COATING | OTI LUMIONICS INC. (CA) | 2023-07-20 | — | — | US | claimed |
| US-20230165124-A1 | METHOD FOR PATTERNING A COATING ON A SURFACE AND DEVICE INCLUDING A PATTERNED COATING | OTI LUMIONICS INC. (CA) | 2023-05-25 | — | — | US | claimed |
| US-11581487-B2 | Patterned conductive coating for surface of an opto-electronic device | OTI LUMIONICS INC. (CA) | 2023-02-14 | — | — | US | claimed |
| CN-110746369-B | Method for synthesizing 4-amido isoxazole | 华南理工大学 | 2022-06-14 | — | — | CN | claimed |
| CN-110746369-A | Method for synthesizing 4-acylamino isoxazole | 华南理工大学 | 2020-02-04 | — | — | CN | claimed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | claimed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | claimed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | claimed |
| EP-1978967-B1 | QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | claimed |
| WO-2007135529-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| EP-1091930-B1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS INC (US) | 2006-12-13 | — | — | EP | claimed |
| US-7053056-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | claimed |
| US-6544951-B2 | Antiinflammatory agents; autoimmune diseases, nervous system degradation | IDUN PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | claimed |
| US-6521667-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | claimed |
| EP-0798291-B1 | NOVEL 1,3-DIALKYLUREA DERIVATIVES | SANTEN PHARMACEUTICAL CO LTD (JP) | 2002-09-11 | — | — | EP | claimed |
| US-5968980-A | ENDOPEPTIDASE 24.11 INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1999-10-19 | — | — | US | claimed |
| EP-0798291-A1 | NOVEL 1,3-DIALKYLUREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1997-10-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240114784-A1 | ORGANIC LIGHT EMITTING DEVICE | CRY1, CRY2, CYBA | TSHR 4436/4885ACHE 354/4885NPC1 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.